Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world

by Tjalf Ziemssen, Katja Thomas
Published 2017-10-01

Cortisol awakening response is linked to disease course and progression in multiple sclerosis.

by Simone Kern, Ivonne Krause, Antje Horntrich, Katja Thomas, Julia Aderhold, Tjalf Ziemssen
Published 2013-01-01

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

by Tjalf Ziemssen, Hayrettin Tumani, Tony Sehr, Katja Thomas, Friedemann Paul, Nils Richter, Emil Samara, Ofer Spiegelstein, Ella Sorani, Oren Bar-Ilan, Dorit Mimrod, Liat Hayardeny
Published 2017-08-01